e-ISSN 1309-2545      ISSN 1301-062X

Download Current Issue.

Volume : 28 Issue : 2 Year : 2022

Current Issue Archive Popular Articles Ahead of Print Submit Your Article Login Copyright Transfer Form
Turkish Journal of Neurology Indexed By
  Donepezil Treatment of Hypersomnia After COVID-19 [Turk J Neurol]
Turk J Neurol. 2021; 27(1): 43-45 | DOI: 10.4274/tnd.2021.29726  

Donepezil Treatment of Hypersomnia After COVID-19

Demet Aygün Üstel, Pervin İşeri, Meltem Can İke
Istanbul Atlas University Faculty of Medicine, Department of Neurology, Istanbul, Turkey

The long-term effects of coronavirus disease-2019 (COVID-19) are not yet fully understood and some are due to central nervous system involvement. COVID-19 was reported to cause fatigue in some people after a long-term viral illness, characterized by daytime wakefulness and disturbed sleep cycles. Herein, a 90-yearold patient is presented, who developed hypersomnia after COVID-19 and showed signs of cortical atrophy in the left chronic thalamic infarction area and bilateral temporal lobe anteromedial parts in cranial magnetic resonance imaging, as well as increased wakefulness with donepezil treatment. Donepezil is an acetylcholinesterase inhibitor that increases the level of acetylcholinesterase that inhibits gamma-aminobutyric acid release in the forebrain via the serotonin system, which increases dopamine levels in the nucleus accumbens. The serotonin system has been noted for its positive effect on excessive sleepiness and Epworth sleepiness scale score improvement.

Keywords: COVID-19, ultradian rhythm, hypersomnia, donepezil

Demet Aygün Üstel, Pervin İşeri, Meltem Can İke. Donepezil Treatment of Hypersomnia After COVID-19. Turk J Neurol. 2021; 27(1): 43-45

Corresponding Author: Demet Aygün Üstel, Türkiye

English Full Text
Download citation
Reference Manager
Share with email
Send email to author

Similar articles
Google Scholar

© Copyright 2022 Turkish Journal of Neurology
Home        |        Contact
LookUs & OnlineMakale